7 Viruses Viruses Viruses viruses Viruses 1999-4915 Molecular Diversity Preservation International VirusesVirusesviruses viruses-02-00244 viruses-02-00244 10.3390/v2010244 v2010244 Review Virus Infection Recognition and Early Innate Responses to Non-Enveloped Viral Vectors Shayakhmetov Dmitry M. Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195-7720, USA; E-Mail: dshax@u.washington.edu; Tel.: +1-206-543-6773; Fax: +1-206-685-8675 19 01 2010 2 1 244 261 20 10 2009 13 01 2010 14 01 2010 © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland 2010

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Numerous human genetic and acquired diseases could be corrected or ameliorated if viruses are harnessed to safely and effectively deliver therapeutic genes to diseased cells and tissues in vivo. Innate immune and inflammatory response represents one of the key stumbling blocks during the development of viral-based therapies. In this review, current data on the early innate immune responses to viruses and to the most commonly used gene therapy vectors (using adenovirus and adeno-associated virus) will be discussed. Recent findings in the field may help develop new approaches to moderate these innate immune anti-viral responses and thus improve the safety of viral vectors for human gene therapy applications.

virus vectors innate immunity inflammation 2010 1. Introduction

During the millions of years of co-evolution, viral pathogens and their hosts evolved to an equilibrium allowing both hosts and viruses to coexist and thus survive. However, this equilibrium is quasi-stationary due to constant adaptation of viruses to existing or new hosts and to eternal selection within these hosts for the most effective antiviral mechanisms. One of the best testaments to the quasi-stationary nature of the balance between viruses and their hosts is a set of recent reports of unanticipated severe innate immune and inflammatory responses to rather benign viral pathogens used as gene delivery vehicles in human gene therapy trials [1-3]. Viruses are obligate pathogens and are very efficient at infecting host cells that support their reproduction and dissemination. Clinical studies suggest that, in many cases, a small number of virus particles is sufficient to transmit virus-associated disease [4]. Moreover, viruses develop an array of factors and strategies that allow them to evade or modulate the host immune system. These factors facilitate rapid completion of the viral reproductive cycle, contributing to the spread of infection. In response to the ever-present threat from viruses, hosts have evolved molecular mechanisms to detect virus infection and limit virus-induced damage. Abundant information has recently emerged on the molecular mechanism of innate immunity to virus infection in mammals [5]. One of the fundamental principles of virus recognition by the host innate immune system appears to rely on the sensing of virus-associated nucleic acids in infected cells by specialized classes of receptors – Toll-like receptors (TLRs), retinoid acid-inducible gene I (RIG-I)-like receptors (RLRs), and nucleotide oligomerization domain (NOD)-like receptors (NLRs) (Figure 1). This latest evidence also indicates that the host recognition of cell damage or stress induced merely by virus entry into cells is likely to be the second key principle for virus sensing which does not rely on pathogen-associated nucleic acid recognition.

2. Molecular Basis for Cellular Recognition of Virus Infection

The obligate nature of viral pathogens creates a considerable challenge for the host to detect onset and continuation of virus infection. Because viruses replicate in host cells and frequently utilize host protein and nucleic acid processing machineries, host/non-host discrimination becomes complicated based solely on pathogen-specific chemical moiety recognition. However, the natural diversity of virus-associated nucleic acids makes them a legitimate target for detection within infected cells. While mammalian cells under normal physiologic conditions possess only a limited number of nucleic acid types, such as double-stranded (ds) DNA with methylated CpG motifs and single-stranded (ss) RNA with a cap structure at the 5’ end of the molecule, the structure of virus-associated nucleic acids is very diverse. Viruses encode their genetic information in a form of ssDNA, linear dsDNA, circular dsDNA, ssRNA, dsRNA, all with myriads of unique modifications and permutations of polarity and replicative intermediates. Accumulating evidence suggests that host recognition of virus-associated nucleic acids is a fundamental principle for sensing virus infection in mammalian cells.

2.1. TLR-dependent recognition of virus infection

One of the best-studied families of receptors mediating pathogen recognition by the innate immune system are TLRs. There are more than 10 distinct TLR receptors identified in mammals to date [6]. TLR3, TLR7, and TLR9 were shown to recognize viral-associated nucleic acids in the cellular endosomal compartment. TLR3 is activated by a dsRNA [7], TLR7 is activated by a ssRNA [8-10], and TLR9 is activated by an unmethylated CpG DNA motif [11]. While TLR3 is expressed in many cell types, TLR7 and TLR9 are expressed at high levels in plasmacytoid dendritic cells (pDCs) [12]. All TLR-initiated signaling converges on the activation of type I interferon (IFN-I) through the engagement of IRF3 and/or IRF7 transcription factors and the early response inflammatory cytokine genes via activation of NF-κB [13] (Figure 1). Despite this convergence on a specific set of genes, the signaling pathways that lead to IFN-I and cytokine gene activation in response to TLR engagement are cell-type specific and recruit different adaptors and mediators depending on the type of TLR. dsRNA binding to TLR3 ecto-domain in the endosomes leads to receptor dimerization and the recruitment of an adaptor molecule TRIF (also known as TICAM-1) [1416]. TRIF then binds TRAF3 and TRAF6 proteins via TRAF-binding motifs that are present within N-terminal region of TRIF [17]. TRAF6 is responsible for activating NF-κB that leads to the expression of pro-inflammatory cytokines [18]. TRIF, however, can also activate TBK1 and IKKi protein kinases, which phosphorylate IRF3 and lead to its translocation into the nucleus and activation of IFN-I [19,20]. TLR3 plays critical role in controlling replication of MCMV in mice as well as purified reovirus genomic dsRNA is a potent activator of IFN-I in a TLR3-dependent manner [7,21].

Three classes of pattern recognition receptors engaged in sensing viral nucleic acids in infected cells. See text for the detail description of their respective structures, ligand specificities, and roles in inducing host antiviral responses.

In the cellular endosomal compartment, TLR7 and TLR9 recognize ssRNA and unmethylated CpG DNA, respectively [8-11]. Upon engagement of a cognate ligand, TLR7 and TLR9 initiate signaling through a common adaptor molecule myeloid differentiation factor 88 (MyD88) [22]. MyD88 then interacts with IL-1R-associated kinase 4 (IRAK-4) [5]. IRAK-4, in turn, transduces the signal though IRAK-1 and IRAK-2, that leads to the activation of TRAF6. Activation of TRAF6, through a set of protein kinases, results in phosphorylation of mitogen activated protein kinase 6 (MAPK6) and IKK-β, which modulate the activation of NF-κB and MAPKs leading to the production of pro-inflammatory cytokines. In pDCs, activation of TLR7 and TLR9, in addition to inflammatory cytokine production, leads to a MyD88-dependent activation of IRF7 which is responsible for the induction of IFN-I [23,24]. In pDCs, vesicular stomatitis virus (VSV) RNA is recognized by TLR7 upon autophagosome formation [25]. In response to adenovirus infection, pDCs in vitro activate IFN-I production in a TLR-9-dependent manner [26].

 2.2. RLR-dependent recognition of virus infection

Upon entry into host cells, many viral pathogens (specifically those with lipid envelopes such as influenza and human immunodeficiency virus [HIV]) avoid exposure of their genomic nucleic acids to endosomal TLRs. However, activation of IFN-I in response to virus infection is afforded through a cytoplasmic detection of viral RNAs by an RLR family of receptors, consisting of RIG-I and melanoma differentiation-associated gene 5 (MDA5) [27-29]. RIG-I and MDA5 directly bind viral RNA via the helicase domain [30] (Figure 1). Although both RIG-I and MDA-5 can bind dsRNA, MDA-5 activates IFN-I production upon binding of long (>2kb, dsRNA species [31]) while RIG-I induces IFN-I upon binding of short dsRNA and 5’-triphosphate-containing ssRNA [32-34]. Similarly to the TLR receptor family, IFN-I and inflammatory cytokine genes are the principal targets of RLR receptors’ signaling. When the viral RNA binds to and activates RIG-I or MDA5, these proteins engage key adapter protein IFN-β promoter stimulator-1 (IPS-1), also known as mitochondrial antiviral (MAVS), virus-induced signaling adapter (VISA), or CARD adapter inducing IFN-β (CARDIFF) [35-38]. Activated IPS-1 recruits TNFR-associated death domain protein (TRADD) which forms a complex with TRAF3 and receptor-interacting protein RIP-1 [39]. TRAF3 is critical for IFN-I induction and mediates activation of TBK1 and IKKi kinases which phosphorylate IRF3 and IRF7, leading to activation of IFN-I and a set of IFN-I-inducible genes [20,40]. IPS-1 also is critical for the activation of inflammatory cytokine genes mediated by NF-κB via phosphorylation of classical IKKα/β kinases.

MDA-5 and RIG-I are important for activating host responses to RNA viruses. RIG-I was shown to activate IFN-I in response to paramyxoviruses, VSV, influenza virus, hepatitis C virus, and Japanese encephalitis virus infection [41-44]. MDA5 is critical for IFN-I production in response to reoviruses [31] and picornaviruses, including encephalomyocarditis virus (ECMV) and Theiler’s virus [45]. Mice that lack both MDA5 and RIG-I are highly susceptible to VSV and EMCV virus infection [5,29]. Collectively, cytoplasmic detection of viral RNAs by RLR appears to be the key pathway of host innate immunity activation by RNA viral pathogens.

 2.3. NLR-dependent recognition of virus infection

NLR family consists of a relatively large number of intracellular receptors with a prototypic tripartite structure [46,47]. The N-terminus is composed of either a caspase recruitment domain (CARD) or a Pyrin domain (PYD) that are important for signal transduction. The central part of the NLR molecule is composed of a nucleotide-binding domain (NBD) critical for ATP binding and oligomerization. The C-terminus is composed of a leucine-rich repeat (LRR) domain, important for ligand binding and autoregulation of the NLR function [48]. Upon engagement of a LRR-specific ligand, NBD binds ATP, leading to oligomerization of the NLR and initiation of a signal transduction via N-terminal domain binding specific adaptors, then leads to the activation of MAPK kinases and NF-κB (in case of a PYD N-terminal domain), or association of NLR with a supramolecular complex of proteins called “inflammasome” via CARD domain [49]. In addition to an NLR, inflammasome includes ASC adapter protein and inflammatory caspases, such as caspase-1 [50] (Figure 1). Upon activation of NLR and its recruitment into the inflammasome complex, pro-caspase-1 is processed into functionally active caspase-1, which further cleaves pre-IL-1β into mature IL-1β, leading to its release from cells and activation of the IL-1R signaling pathway.

There is abundant evidence demonstrating the essential role of NLRs in sensing and controlling microbial infection in mammalian cells [51]. Regarding the NLR involvement in recognition of viral infection, recent data indicate that the NLR family member NLRP3 (also called Cryopyrin) plays an essential role in sensing viral and microbial DNA in macrophages in vitro [52]. Recent data also suggest that NLRP3 mediates recognition of influenza A virus infection [53,54]. Mice deficient for NLRP3 exhibit dramatically increased mortality and reduced immune response to the influenza virus. NLRP3 inflammasome activation by influenza virus was dependent on lysosomal maturation and reactive oxygen species. It was also suggested that NLRP3 inflammasome is involved in sensing viral RNA [53], while another study also implicates NLRP3 inflammasome in the resolution of inflammation [54].

 2.4. Recognition of cytoplasmic dsDNA by DAI and AIM2

Intra-cytoplasmic detection of dsDNA represents an important mechanism for the detection of viral and microbial pathogens. Although several studies clearly showed that cells transfected with dsDNA leads to activation of IFN-I and NF-κB-dependent inflammatory cytokines, the molecular sensors of dsDNA in the cytoplasm that remained unidentified until recently. Takaoka et al. showed that dsDNA-dependent activation of IFN-I production in cells is mediated by a protein named DNA-dependent activator of IFN-regulatory factors (DAI) [55]. DAI was also known as Z-DNA binding protein ZBP-1 and DLM-1 and was shown to directly bind dsDNA via its Zα and Zβ DNA binding domains that are homologous to the nucleic acid binding domain adenosine deaminase acting on RNase1 (ADAR1) of an RNA-editing protein. Although DAI binds left-handed Z-form DNA with high affinity, it also binds B-form DNA and activates phosphorylation of IRF3 via TBK-1 serine/threonine kinase [56]. Inhibition of DAI using siRNA reduced activation of IFN-I production in response to human herpesvirus 1 (HSV-1), suggesting its potential role in detecting and mounting innate immune responses to DNA viruses.

Most recently, four groups independently reported the identification of a protein absent in melanoma 2 (AIM2) as a specific sensor of dsDNA in the cytoplasm [57-60]. AIM2 binds dsDNA via its C-terminal HIN-200 (hematopoietic interferon-inducible nuclear proteins with a 200–amino acid repeat) domain and this binding leads to oligomerization of the protein [61]. The N-terminal PYD domain of oligomerized AIM2 is capable of recruiting both ASC and caspase-1 inflammasome components and drives the activation of caspase-1 that then leads to IL-1β pre-protein processing and release of mature IL-1β. Knockdown of Aim2 abrogates caspase-1 activation in response to cytoplasmic dsDNA and the dsDNA vaccinia virus in vitro. However, AIM2 appears to not be normally present in the cytoplasm of uninfected cells and its expression depends on cell stimulation with IFN-I. This data suggests that, although AIM2 is critical for activation of inflammasome by dsDNA, it is unlikely to play a role in early recognition of viral infection. Instead, early stages of virus infection may activate IFN-I, which in turn leads to AIM2 expression that assists executing phases of innate immunity activation, such as processing and release of pre-synthesized IL-1β, if dsDNA is present in the cytoplasm.

3. Specifics of Innate Host Responses to Viral Gene Therapy Vectors

The existence of an array of specific receptors enabling detection of viruses within the cell is counterbalanced by numerous evasion strategies and mechanisms developed by virus pathogens. For instance, hepatitis C virus (HCV) encodes protein NS3/4A that cleaves IPS-1 and thus prevents IFN-I induction upon virus infection [62,63]. The packaging of viral genomic nucleic acids in association with virus-encoded DNA- or RNA-binding proteins may also represent a strategy to avoid detection of viral genomes in infected cells by TLRs, NLRs, or RLRs.

To achieve the goal of correcting human diseases, viral vectors for gene therapy must be able to safely and effectively deliver therapeutic genes to disease sites. However, the incorporation of therapeutic genes, along with all the necessary regulatory elements to guide tissue-specific transgene expression, often requires deletion of viral genes that are dispensable for vector production. Moreover, many viral vectors are based on attenuated forms of viruses that were specifically modified to reduce their virulence and prevent the re-emergence of their fully virulent forms. Most frequently such modifications of viruses are made at the expense of viral genes that counteract host innate and adaptive immunity. This makes viral vectors more prone to induce strong innate and/or adaptive immune responses. Another important consideration that may play a role in the induction of potent innate immune and inflammatory responses to viral vectors is that drastically higher doses of virus particles are delivered in vivo for therapeutic gene transfer, compared to doses that initiate natural virus infection. Indeed, a handful of wild type adenovirus particles are sufficient to induce a respiratory disease but in gene therapy trials adenovirus vectors may be delivered either locally or systemically at a single bolus dose of >10x1012 virus particles [1]. Clearly, the exposure of host cells to such a massive number of virus particles could initiate host responses that may be vastly distinct in magnitude and severity compared to those observed upon natural virus infection. One of the currently emerging concepts implies that due to the high vector doses that are needed to achieve efficient gene transfer and therapeutic gene expression, the activation of innate immunity to gene therapy vectors occurs due to the engagement of mechanisms that are naturally responsible for the detection of host cell damage or stress.

4. Innate Responses to Adenovirus Vectors

Adenovirus vectors (Ads) are the second most frequently used vectors in clinical trials in the US to treat numerous inborn and acquired human diseases, including cystic fibrosis and cancer [64]. Interest in Ad has recently increased considerably due to its potential as a vector for vaccination against life threatening infectious agents including anthrax [65,66]. Many of these potential applications will ultimately require intravenous Ad administration to achieve the desired therapeutic goals. Since a patient tragically died due to disseminated intravascular coagulation, systemic inflammation and multiple organ failure after Ad administration via the hepatic artery during a gene therapy trial in 1999 [3], major concerns have risen regarding the safety of systemic Ad injection. A decade later, the mechanistic aspects of and molecular pathways involved in triggering acute anti-Ad inflammatory response still remain poorly defined. Recent studies strongly suggest that the immediate innate immune response towards intravenously delivered Ads consists of several discrete components and include cytokine activation, pro-inflammatory Mφ death, and influx of inflammatory leukocytes into affected sites.

4.1. Molecular mediators of early innate immune responses to Ad vectors

Even though natural infections with Ads are largely harmless in humans, an intravenous Ad vector administration for gene delivery purposes, especially at high doses, stimulates strong innate and adaptive immune responses and can be fatal for the host [1-3,67,68]. Upon systemic application of Ads in rodents, rhesus monkeys, and humans, a rapid liver-mediated vector removal from circulation was observed [68-74]. After intravenous delivery, Ads induce two phases of inflammatory gene expression in the liver. The first phase of acute inflammation occurs within 24 h of virus administration, and is entirely dependent on virus capsid interactions with the host cells [75]. The second phase begins 3-4 days after Ad administration and requires viral gene expression [76]. In animal models, intravenous Ad administration has been shown to induce transcription and release into the blood of a number of cytokines and chemokines, including IFN-I, IL-6, TNF-α, RANTES, IP-10, IL-8, MIP-1α, MIP-1β and MIP-2 [76-82]. Macrophages, including tissue residential macrophages (e.g., Kupffer cells in the liver), and dendritic cells throughout the body are considered to be the primary source of these cytokines and chemokines following their transduction with Ads [75]. Additionally, a rapid clearance of Ad from circulation by Kupffer cells may have a protective role against the dissemination of Ads to lymphoid organs, therefore reducing systemic inflammation. In several gene therapy clinical trials, serum levels of IL-6, IL-10 and IL-1 were elevated [83-86] after intravenous Ad administration at high doses (2x1012 – 6x1013 virus particles). The role of these cytokines in the initiation of an immediate innate immune response remains unclear. Histological evaluation of tissues, including lung, liver, and spleen, revealed areas of leukocyte and neutrophil infiltration as well as infarcts ([79,87], and our unpublished observation), indicating that most tissues in the body are involved in the inflammatory response to Ad after intravenous virus injection. It has been widely accepted that Ad-mediated liver damage plays a central role in the pathogenesis of acute systemic inflammation caused by intravenous Ad administration. To this end, it has been found that the activation of MIP-2 chemokine is at least partially responsible for neutrophil attraction to liver tissue, and that inactivation of MIP-2 with an anti-MIP-2 antibody ameliorates liver pathology after intravenous Ad administration [79]. To date, accumulating evidence suggests that Ad triggers highly complex multifaceted innate immune and inflammatory responses, which are reflected at a clinical level in cytokinemia, thrombocytopenia, complement activation, disseminated intravascular coagulation, and multiple organ failure due to (at least in part) collateral damage from infiltrating pro-inflammatory leukocytes. Despite considerable recent progress in defining early mediators of Ad-induced inflammation [26,52,88-90], the unifying mechanistic description of the sequential events that lead from early Ad-host cell interactions to clinical signs of Ad-triggered systemic toxicity remains illusive.

 4.2. Molecular sensors of Ad infection

Using microarray technology, it was found that adenovirus infection rapidly dysregulates expression of up to 15% of all mRNA transcripts in mouse liver tissue or in human epithelial A549 cells [91,92]. These data prompted the search for intracellular sensor molecules that might be involved in recognition of adenovirus capsid components that can be collectively called molecular sensors of adenovirus infection.

From earlier studies it was established that the expression of genes involved in innate immune and inflammatory responses was significantly up-regulated shortly after Ad vector delivery, but prior to initiation of viral gene expression. In mouse and non-human primate models, Wilson and co-workers demonstrated activation of innate responses by transcriptionally-defective adenovirus particles [77,78]. Consistent with these findings, severe acute inflammatory response was also observed in a non-human primate model after the intravenous delivery of a helper-dependent Ad vector which lacked all viral genes [1]. These data directly demonstrate that the dose-dependent activation of innate immune and inflammatory responses are primarily mediated by adenovirus particle interaction with host cells and do not require viral gene expression.

Due to the central role of TLRs in detecting invading pathogens, considerable efforts were made to determine if this family of receptors is involved in the recognition of Ad infection. Recent data suggest that in response to Ad, plasmacytoid dendritic cells secrete type-I IFN in a TLR-9-dependent manner [93,94]. It is of interest that human cell lines expressing TLR9, permissive to infection by both coxsackievirus and adenovirus receptor (CAR)- and CD46-interacting Ad serotypes, showed a preferential activation of TLR9-mediated signaling by CD46-interacting serotypes [93]. These data are consistent with earlier findings that CD46-interacting Ads select an alternate intracellular trafficking pathway and reside in late endosomal compartments for longer times, compared to CAR-interacting Ad serotypes [95]. Because TLR9 expression is localized to late endosomal compartments, it appears that Ad DNA may activate TLR9 and induce type-I IFN expression. Using helper-dependent Ad vectors, Curello et al. found that the immediate innate immune response, assessed by plasma levels of IL-6 and IL-12, was partially attenuated in TLR9 knockout mice, when compared to the control group expressing wild type levels of TLR9 [96]. The involvement of TLR-mediated pathways in the induction of anti-Ad host responses was further analyzed in wild type and MyD88-knockout mice. These studies provided evidence that IFN-I is induced in response to Ad infection both in MyD88-dependent and -independent manner. For instance, plasmacytoid DCs produced IFNα/β in a TLR9 and MyD88-dependent manner, however, conventional DCs and macrophages initiated IFN-I production through a MyD88-independent mechanism, which likely involved an as yet unidentified cytosolic sensor of DNA [26]. In a very thorough study by Nociari et al., the authors provide further evidence that IFN-I expression in response to cell infection with Ad vectors occurs in a MyD88-independent manner. This data supports the idea that Ad DNA is likely detected by an unidentified sensor of nucleic acids in the cytoplasm [89]. This group provided compelling evidence that the Ad genomic dsDNA can induce phosphorylation of interferon regulatory factor IRF3, which is the key transcription factor in activating the antiviral IFN-I mediated signaling pathway. In a more recent paper, Fejer et al. demonstrated that plasmocytoid DCs are the principal source of type I IFN, which is activated 2-4 hours after intravenous Ad administration [88]. These authors also defined IRF7 as a critical mediator of Ad-induced IFN-I activation in vivo.

Recently, Muruve et al. reported that the NLRP3 inflammasome recognizes cytosolic microbial and host DNA and triggers the activation of host innate immune responses [52]. In addition to plasmid or bacterial DNA, the authors used Ad to demonstrate the involvement of NLRP3 inflammasome in cytosolic DNA sensing. Based on data obtained using in vitro systems 6 hours after virus infection, it was proposed that Ad is sensed by macrophages when virus particles reach for the cytosol and expose viral genomic DNA to the NLRP3 inflammasome sensor, which, via ASC, activates caspase-1 processing, that leads to IL-1β maturation and release. However, recent data from our laboratory strongly argues against the critical role of NLRP3 inflammasome in sensing Ad entry into cells in vivo and activating innate immune and inflammatory anti-Ad responses. Using a set of mice deficient for critical mediators of innate immunity and inflammation, we demonstrated that macrophage-derived IL-1α is the principal activator of the innate immune response to Ad in vivo [97]. Activation of IL-1α did not require MyD88-, TRIF-, or TRAF6-signaling, and occurred in mice deficient for IL-1β, IFN-IR, or inflammasome components caspase-1, ASC, and NLRP3. These findings strongly suggest that signaling pathways that were earlier implicated in the activation of an innate antiviral response and leading to IFN-I production [5] are not involved in triggering inflammatory and innate immune responses to Ad. Our studies also demonstrated that the IL-1α-mediated response critically depends on viral RGD motif-mediated binding to macrophage β3 integrins, which occurs prior to the internalization of the virus into the cell [98,99]. However, the magnitude of inflammatory response to Ad was greatly amplified by the virus-mediated endosome rupture. Because IL-1α is a key mediator of host inflammatory responses to dying cells [100], our studies strongly suggest that host cells trigger the activation of innate immunity to Ads via engaging cell damage or endosomal stress response mechanisms, rather than via sensing genomic Ad DNA within infected cells. However, in some specialized cell types like pDCs, sensing of Ad DNA by TLR9 may also contribute to the induction of innate anti-Ad responses [26]. Considering the major progress in our understanding of Ad-host interactions in recent years, it is conceivable that a comprehensive model of activation of innate immune and inflammatory responses by Ad in vivo will emerge in the near future.

5. Innate Responses to Adeno-Associated Virus Vectors

To date, numerous pre-clinical and clinical studies demonstrated that viral vectors based on adeno-associated virus (AAV) are relatively safe when delivered via an intravenous route and do not induce robust innate immune and inflammatory responses [101,102]. However, the host innate immune system plays a central role in shaping the outcome of a gene delivery using AAV-based vector systems [103]. The earlier studies clearly demonstrated that when injected intravenously into mice at high doses, AAV induces transcriptional activation of inflammatory cytokine and chemokine genes, including TNF-α, RANTES, MIP-1β, MIP-2, MCP-1, and IP-10. Moreover, the absolute amounts of these cytokines and chemokines in the liver 1 hour after virus injection were comparable for AAV and Ads [104]. Although the expression of these genes greatly receded by 6 hours after AAV (but not Ad) administration, this data indicates that the AAV cell entry process and/or early interactions with host cells triggers the activation of signaling pathways that initiate the unraveling of a stereotypic pro-inflammatory host response. The same study further showed that Kupffer cells were primarily responsible for the activation of these pro-inflammatory genes in the liver after AAV administration [104].

Because adaptive immunity represents a principal barrier for successful gene transfer using AAV-based vectors [103], much effort was made to understand the AAV interaction with professional antigen-presenting cells, specifically DCs. In a most recent and very detailed study by Zhu et al., the authors found that AAV is recognized by pDCs via TLR9-MyD88-dependent pathway [105]. As noted above, in this specialized cell type, TLR-MyD88 pathway is coupled to IRF7 activation that leads to IFN-I production. Zhu et al. further demonstrated that AAV-mediated induction of IFN-I in pDCs is completely dependent on TLR9 and MyD88 in vitro. Importantly, they further demonstrated that TLR9-MyD88 pathway was critical for the activation of CD8+ T cell responses to both the transgene product and AAV capsid in vivo, leading to the generation of both transgene product-specific and AAV capsid-specific neutralizing antibodies [105]. Collectively, these data are fundamental for our understanding of the AAV-based vector recognition by the host cells and for the development of approaches to modulate the innate immune system to reduce vector recognition and improve therapeutic transgene expression in the target cells.

 6. Conclusions

The wealth of new data on molecular sensors of viral infection that emerged during the last two years creates an opportunity for the development of basic paradigms of virus infection recognition in mammalian cells. One of the fundamental principles of virus-host discrimination by the innate immune system appears to rely on recognition of virus-associated nucleic acids by the specialized families of receptors TLRs, RLRs, and NLRs. While the TLR receptors function at the cell surface and within the cellular endosomal compartments, RLR and NLRs function within the cellular cytoplasm. Although the engagement of TLRs and RLRs triggers the activation of signal transduction pathways leading to the inflammatory cytokine and chemokine gene expression, NLRs are critical for the executive stages of innate immunity activation and process inflammatory caspases and inflammasome-dependent cytokines.

The activation of innate immune responses to viral vectors also occurs via the engagement of TLRs and NLRs. However, in addition to direct detection of their genomic nucleic acids, host cells may recognize viral vectors though an indirect sensing of cell damage or stress that occurs due to a high vector dose delivery frequently employed in gene transfer protocols. Importantly, it was found that in response to viral vectors, different cell types activate distinct signaling pathways that ultimately shape the multifaceted innate immune and inflammatory responses observed in pre-clinical studies and clinical gene therapy trials. Future studies should focus on improving our understanding of cell type-specific pathways and mediators of inflammation in response to the viral vector administration in vivo. This information will be critical for the development of new approaches to selectively modulate these responses and ultimately to improve the safety of viral vector-mediated gene transfer for human gene therapy application.

This work was supported by funding from the US National Institutes of Health grants AI065429 and CA141439 and from a Grand Challenges Explorations grant from the Bill and Melinda Gates Foundation.

 References Brunetti-Pierri N. Palmer D.J. Beaudet A.L. Carey K.D. Finegold M. Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates Hum. Gene Ther. 2004 15 35 46 14965376 Raper S.E. Chirmule N. Lee F.S. Wivel N.A. Bagg A. Gao G.P. Wilson J.M. Batshaw M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer Mol. Genet. Metab. 2003 80 148 158 10.1016/j.ymgme.2003.08.016 14567964 Raper S.E. Yudkoff M. Chirmule N. Gao G.P. Nunes F. Haskal Z.J. Furth E.E. Propert K.J. Robinson M.B. Magosin S. Simoes H. Speicher L. Hughes J. Tazelaar J. Wivel N.A. Wilson J.M. Batshaw M.L. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency Hum. Gene Ther. 2002 13 163 175 11779420 Richman D.D. Whitley R. Hayden F.G. Clinical Virology, 2nd ed. 2002 ASM Press Washington, D.C., USA Takeuchi O. Akira S. Innate immunity to virus infection Immunol. Rev. 2009 227 75 86 10.1111/j.1600-065X.2008.00737.x 19120477 Takeda K. Akira S. Toll-like receptors in innate immunity Int. Immunol. 2005 17 1 14 10.1093/intimm/dxh186 15585605 Alexopoulou L. Holt A.C. Medzhitov R. Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3 Nature 2001 413 732 738 10.1038/35099560 11607032 Diebold S.S. Kaisho T. Hemmi H. Akira S. Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA Science 2004 303 1529 1531 10.1126/science.1093616 14976261 Heil F. Hemmi H. Hochrein H. Ampenberger F. Kirschning C. Akira S. Lipford G. Wagner H. Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 2004 303 1526 1529 10.1126/science.1093620 14976262 Lund J.M. Alexopoulou L. Sato A. Karow M. Adams N.C. Gale N.W. Iwasaki A. Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7 Proc. Natl. Acad. Sci. USA 2004 101 5598 5603 10.1073/pnas.0400937101 Hemmi H. Takeuchi O. Kawai T. Kaisho T. Sato S. Sanjo H. Matsumoto M. Hoshino K. Wagner H. Takeda K. Akira S. A Toll-like receptor recognizes bacterial DNA Nature 2000 408 740 745 10.1038/35047123 11130078 Colonna M. Trinchieri G. Liu Y.J. Plasmacytoid dendritic cells in immunity Nat. Immunol. 2004 5 1219 1226 10.1038/ni1141 15549123 Kawai T. Akira S. TLR signaling Semin. Immunol. 2007 19 24 32 10.1016/j.smim.2006.12.004 17275323 Hoebe K. Du X. Georgel P. Janssen E. Tabeta K. Kim S.O. Goode J. Lin P. Mann N. Mudd S. Crozat K. Sovath S. Han J. Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling Nature 2003 424 743 748 10.1038/nature01889 12872135 Oshiumi H. Matsumoto M. Funami K. Akazawa T. Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction Nat. Immunol. 2003 4 161 167 10.1038/ni886 Yamamoto M. Sato S. Mori K. Hoshino K. Takeuchi O. Takeda K. Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling J. Immunol. 2002 169 6668 6672 12471095 Yamamoto M. Sato S. Hemmi H. Hoshino K. Kaisho T. Sanjo H. Takeuchi O. Sugiyama M. Okabe M. Takeda K. Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway Science 2003 301 640 643 10.1126/science.1087262 12855817 Deng L. Wang C. Spencer E. Yang L. Braun A. You J. Slaughter C. Pickart C. Chen Z.J. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain Cell 2000 103 351 361 10.1016/S0092-8674(00)00126-4 11057907 Sharma S. tenOever B.R. Grandvaux N. Zhou G.P. Lin R. Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway Science 2003 300 1148 1151 10.1126/science.1081315 12702806 Fitzgerald K.A. McWhirter S.M. Faia K.L. Rowe D.C. Latz E. Golenbock D.T. Coyle A.J. Liao S.M. Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway Nat. Immunol. 2003 4 491 496 10.1038/ni921 12692549 Tabeta K. Georgel P. Janssen E. Du X. Hoebe K. Crozat K. Mudd S. Shamel L. Sovath S. Goode J. Alexopoulou L. Flavell R. A. Beutler B. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection P. Natl. Acad. Sci. USA 2004 101 3516 3521 10.1073/pnas.0400525101 Takeuchi O. Takeda K. Hoshino K. Adachi O. Ogawa T. Akira S. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades Int. Immunol. 2000 12 113 117 10.1093/intimm/12.1.113 10607756 Honda K. Yanai H. Mizutani T. Negishi H. Shimada N. Suzuki N. Ohba Y. Takaoka A. Yeh W.C. Taniguchi T. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling Proc. Natl. Acad. Sci. USA 2004 101 15416 15421 10.1073/pnas.0406933101 Kawai T. Sato S. Ishii K.J. Coban C. Hemmi H. Yamamoto M. Terai K. Matsuda M. Inoue J. Uematsu S. Takeuchi O. Akira S. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6 Nat. Immunol. 2004 5 1061 1068 10.1038/ni1118 15361868 Lee H.K. Lund J.M. Ramanathan B. Mizushima N. Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells Science 2007 315 1398 1401 10.1126/science.1136880 17272685 Zhu J.G. Huang X.P. Yang Y.P. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways J. Virol. 2007 81 3170 3180 10.1128/JVI.02192-06 17229689 Kang D.C. Gopalkrishnan R.V. Wu Q. Jankowsky E. Pyle A.M. Fisher P.B. mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties Proc. Natl. Acad. Sci. USA 2002 99 637 642 10.1073/pnas.022637199 Yoneyama M. Kikuchi M. Natsukawa T. Shinobu N. Imaizumi T. Miyagishi M. Taira K. Akira S. Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses Nat. Immunol. 2004 5 730 737 10.1038/ni1087 15208624 Loo Y.M. Fornek J. Crochet N. Bajwa G. Perwitasari O. Martinez-Sobrido L. Akira S. Gill M.A. Garcia-Sastre A. Katze M.G. Gale Jr. M. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity J. Virol. 2008 82 335 345 10.1128/JVI.01080-07 17942531 Yoneyama M. Kikuchi M. Matsumoto K. Imaizumi T. Miyagishi M. Taira K. Foy E. Loo Y.M. Gale Jr. M. Akira S. Yonehara S. Kato A. Fujita T. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity J. Immunol. 2005 175 2851 2858 16116171 Kato H. Takeuchi O. Mikamo-Satoh E. Hirai R. Kawai T. Matsushita K. Hiiragi A. Dermody T.S. Fujita T. Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5 J. Exp. Med. 2008 205 1601 1610 10.1084/jem.20080091 18591409 Hornung V. Ellegast J. Kim S. Brzozka K. Jung A. Kato H. Poeck H. Akira S. Conzelmann K.K. Schlee M. Endres S. Hartmann G. 5 '-triphosphate RNA is the ligand for RIG-I Science 2006 314 994 997 10.1126/science.1132505 17038590 Pichlmair A. Schulz O. Tan C.P. Naslund T.I. Liljestrom P. Weber F. Sousa C.R.E. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5 '-phosphates Science 2006 314 997 1001 10.1126/science.1132998 17038589 Schmidt A. Schwerd T. Hamm W. Hellmuth J.C. Cui S. Wenzel M. Hoffmann F.S. Michallet M.C. Besch R. Hopfner K.P. Endres S. Rothenfusser S. 5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I Proc. Natl. Acad. Sci. USA 2009 106 12067 12072 10.1073/pnas.0900971106 Kawai T. Takahashi K. Sato S. Coban C. Kumar H. Kato H. Ishii K.J. Takeuchi O. Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction Nat. Immunol. 2005 6 981 988 10.1038/ni1243 Meylan E. Curran J. Hofmann K. Moradpour D. Binder M. Bartenschlager R. Tschopp R. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus Nature 2005 437 1167 1172 10.1038/nature04193 16177806 Seth R.B. Sun L.J. Ea C.K. Chen Z.J.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappa B and IRF3 Cell 2005 122 669 682 10.1016/j.cell.2005.08.012 16125763 Xu L.G. Wang Y.Y. Han K.J. Li L.Y. Zhai Z.H. Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling Mol. Cell 2005 19 727 740 10.1016/j.molcel.2005.08.014 16153868 Michallet M.C. Meylan E. Ermolaeva M.A. Vazquez J. Rebsamen M. Curran J. Poeck H. Bscheider M. Hartmann G. Konig M. Kalinke U. Pasparakis M. Tschopp J. TRADD protein is an essential component of the RIG-like helicase antiviral pathway Immunity 2008 28 651 661 10.1016/j.immuni.2008.03.013 18439848 Oganesyan G. Saha S.K. Guo B. He J.Q. Shahangian A. Zarnegar B. Perry A. Cheng G. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response Nature 2006 439 208 211 10.1038/nature04374 16306936 Melchjorsen J. Jensen S.B. Malmgaard L. Rasmussen S.B. Weber F. Bowie A.G. Matikainen S. Paludan S.R. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner J. Virol. 2005 79 12944 12951 10.1128/JVI.79.20.12944-12951.2005 16188996 Sumpter Jr. R. Loo Y.M. Foy E. Li K. Yoneyama M. Fujita T. Lemon S.M. Gale Jr. M. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I J. Virol. 2005 79 2689 2699 10.1128/JVI.79.5.2689-2699.2005 15708988 Kato H. Sato S. Yoneyama M. Yamamoto M. Uematsu S. Matsui K. Tsujimura T. Takeda K. Fujita T. Takeuchi O. Akira S. Cell type-specific involvement of RIG-I in antiviral response Immunity 2005 23 19 28 10.1016/j.immuni.2005.04.010 16039576 Kato H. Takeuchi O. Sato S. Yoneyama M. Yamamoto M. Matsui K. Uematsu S. Jung A. Kawai T. Ishii K.J. Yamaguchi O. Otsu K. Tsujimura T. Koh C.S. Reis e Sousa C. Matsuura Y. Fujita T. Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses Nature 2006 441 101 105 10.1038/nature04734 16625202 Gitlin L. Barchet W. Gilfillan S. Cella M. Beutler B. Flavell R.A. Diamond M.S. Colonna M. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus Proc. Natl. Acad. Sci. U S A 2006 103 8459 8464 10.1073/pnas.0603082103 16714379 Ye Z. Ting J.P. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family Curr. Opin. Immunol. 2008 20 3 9 18280719 Ting J.P.Y. Willingham S.B. Bergstralh D.T. NLRs at the intersection of cell death and immunity Nat. Rev. Immunol. 2008 8 372 379 10.1038/nri2296 Lich J.D. Ting J.P. CATERPILLER (NLR) family members as positive and negative regulators of inflammatory responses Proc. Am. Thorac. Soc. 2007 4 263 266 10.1513/pats.200701-022AW Sutterwala F.S. Ogura Y. Flavell R.A. The inflammasome in pathogen recognition and inflammation J. Leukocyte Biol. 2007 82 259 264 10.1189/jlb.1206755 Lamkanfi M. Kanneganti T.D. Franchi L. Nunez G. Caspase-1 inflammasomes in infection and inflammation J. Leukoc. Biol. 2007 82 220 225 10.1189/jlb.1206756 17442855 Martinon F. Mayor A. Tschopp J. The inflammasomes: guardians of the body Annu. Rev. Immunol. 2009 27 229 265 10.1146/annurev.immunol.021908.132715 19302040 Muruve D.A. Petrilli V. Zaiss A.K. White L.R. Clark S.A. Ross P.J. Parks R.J. Tschopp J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response Nature 2008 452 103 107 10.1038/nature06664 18288107 Allen I.C. Scull M.A. Moore C.B. Holl E.K. McElvania-TeKippe E. Taxman D.J. Guthrie E.H. Pickles R.J. Ting J.P. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA Immunity 2009 30 556 565 10.1016/j.immuni.2009.02.005 19362020 Thomas P.G. Dash P. Aldridge Jr. J.R. Ellebedy A.H. Reynolds C. Funk A.J. Martin W.J. Lamkanfi M. Webby R.J. Boyd K.L. Doherty P.C. Kanneganti T.D. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1 Immunity 2009 30 566 575 10.1016/j.immuni.2009.02.006 19362023 Takaoka A. Wang Z. Choi M.K. Yanai H. Negishi H. Ban T. Lu Y. Miyagishi M. Kodama T. Honda K. Ohba Y. Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response Nature 2007 448 501 505 10.1038/nature06013 17618271 Ishii K.J. Coban C. Kato H. Takahashi K. Torii Y. Takeshita F. Ludwig H. Sutter G. Suzuki K. Hemmi H. Sato S. Yamamoto M. Uematsu S. Kawai T. Takeuchi O. Akira S. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA Nat. Immunol. 2006 7 40 48 10.1038/ni1282 16286919 Roberts T.L. Idris A. Dunn J.A. Kelly G.M. Burnton C.M. Hodgson S. Hardy L.L. Garceau V. Sweet M.J. Ross I.L. Hume D.A. Stacey K.J. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA Science 2009 323 1057 1060 10.1126/science.1169841 19131592 Hornung V. Ablasser A. Charrel-Dennis M. Bauernfeind F. Horvath G. Caffrey D.R. Latz E. Fitzgerald K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC Nature 2009 458 514 518 10.1038/nature07725 19158675 Fernandes-Alnemri T. Yu J.W. Datta P. Wu J. Alnemri E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA Nature 2009 458 509 513 10.1038/nature07710 19158676 Burckstummer T. Baumann C. Bluml S. Dixit E. Durnberger G. Jahn H. Planyavsky M. Bilban M. Colinge J. Bennett K.L. Superti-Furga G. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome Nat. Immunol. 2009 10 266 272 10.1038/ni.1702 19158679 Schroder K. Muruve D.A. Tschopp J. Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome Curr. Biol. 2009 19 R262 R265 10.1016/j.cub.2009.02.011 19321146 Chen Z. Benureau Y. Rijnbrand R. Yi J. Wang T. Warter L. Lanford R.E. Weinman S.A. Lemon S.M. Martin A. Li K. GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS J. Virol. 2007 81 964 976 10.1128/JVI.02076-06 17093192 Baril M. Racine M.E. Penin F. Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease J. Virol. 2009 83 1299 1311 10.1128/JVI.01659-08 19036819 Hutchin M.E. Pickles R.J. Yarbrough W.G. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression Hum. Gene Ther. 2000 11 2365 2375 11096441 Kobinger G.P. Simian adenoviral vector expressing Ebola glycoprotein variants for safe establishment of a strong protective immunity Mol. Ther. 2003 7 S310 Tan Y H.N. Crystal R.G. Rapid protective immunity evoked against anthrax lethal toxin following a single intramuscular administration of an adenovirus-based vaccine coding for humanized protective antigen Mol. Ther. 2003 7 S311 Morral N. O'Neal W.K. Rice K. Leland M.M. Piedra P.A. Aguilar-Cordova E. Carey K.D. Beaudet A.L. Langston C. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons Hum. Gene. Ther. 2002 13 143 154 11779418 Lozier J.N. Csako G. Mondoro T.H. Krizek D.M. Metzger M.E. Costello R. Vostal J.G. Rick M.E. Donahue R.E. Morgan R.A. Toxicity of a first-generation adenoviral vector in rhesus macaques Hum. Gene Ther. 2002 13 113 124 11779415 Alemany R. Suzuki K. Curiel D.T. Blood clearance rates of adenovirus type 5 in mice J. Gen. Virol. 2000 81 2605 2609 11038370 Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 2001 8 89 98 10.1038/sj.gt.3301377 11313778 Kirn D. Martuza R.L. Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions Nat. Med. 2001 7 781 787 10.1038/89901 11433341 Tao N. Gao G.P. Parr M. Johnston J. Baradet T. Wilson J.M. Barsoum J. Fawell S.E. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver Mol. Ther. 2001 3 28 35 10.1006/mthe.2000.0227 11162308 Worgall S. Wolff G. Falck-Pedersen E. Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration Hum. Gene Ther. 1997 8 37 44 10.1089/hum.1997.8.1-37 Wolff G. Worgall S. van Rooijen N. Song W.R. Harvey B.G. Crystal R.G. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ J. Virol. 1997 71 624 629 8985392 Liu Q. Muruve D.A. Molecular basis of the inflammatory response to adenovirus vectors Gene Ther. 2003 10 935 940 10.1038/sj.gt.3302036 12756413 Lieber A. He C.Y. Meuse L. Schowalter D. Kirillova I. Winther B. Kay M.A. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors J. Virol. 1997 71 8798 8807 9343240 Schnell M.A. Zhang Y. Tazelaar J. Gao G.P. Yu Q.C. Qian R. Chen S.J. Varnavski A.N. LeClair C. Raper S.E. Wilson J.M. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors Mol. Ther. 2001 3 708 722 10.1006/mthe.2001.0330 11356076 Zhang Y. Chirmule N. Gao G.P. Qian R. Croyle M. Joshi B. Tazelaar J. Wilson J.M. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages Mol. Ther. 2001 3 697 707 10.1006/mthe.2001.0329 11356075 Muruve D.A. Barnes M.J. Stillman I.E. Libermann T.A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo Hum. Gene Ther. 1999 10 965 976 10223730 Borgland S.L. Bowen G.P. Wong N.C. Libermann T.A. Muruve D.A. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB J. Virol. 2000 74 3941 3947 10.1128/JVI.74.9.3941-3947.2000 10756005 Bowen G.P. Borgland S.L. Lam M. Libermann T.A. Wong N.C. Muruve D.A. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B Hum. Gene Ther. 2002 13 367 379 11860704 Bhat N.R. Fan F. Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways Brain Res. 2002 948 93 101 10.1016/S0006-8993(02)02953-0 12383959 Reid T. Galanis E. Abbruzzese J. Sze D. Andrews J. Romel L. Hatfield M. Rubin J. Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial Gene Ther. 2001 8 1618 1626 10.1038/sj.gt.3301512 Crystal R.G. Harvey B.G. Wisnivesky J.P. O'Donoghue K.A. Chu K.W. Maroni J. Muscat J.C. Pippo A.L. Wright C.E. Kaner R.J. Leopold P.L. Kessler P.D. Rasmussen H.S. Rosengart T.K. Hollmann C. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions Hum. Gene Ther. 2002 13 65 100 11779413 Ben-Gary H. McKinney R.L. Rosengart T. Lesser M.L. Crystal R.G. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes Mol. Ther. 2002 6 287 297 10.1006/mthe.2002.0658 12349828 Mickelson C.A. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee. Minutes of meeting March 8-10, 2000 Hum. Gene Ther. 2000 11 2159 2192 11044916 McCoy R.D. Davidson B.L. Roessler B.J. Huffnagle G.B. Janich S.L. Laing T.J. Simon R.H. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles Hum. Gene Ther. 1995 6 1553 1560 10.1089/hum.1995.6.12-1553 Fejer G. Drechsel L. Liese J. Schleicher U. Ruzsics Z. Imelli N. Greber U.F. Keck S. Hildenbrand B. Krug A. Bogdan C. Freudenberg M.A. Key Role of Splenic Myeloid DCs in the IFN-alpha beta Response to Adenoviruses In Vivo Plos Pathog. 2008 4 e1000208 10.1371/journal.ppat.1000208 19008951 Nociari M. Ocheretina O. Schoggins J.W. Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator J. Virol. 2007 81 4145 4157 10.1128/JVI.02685-06 17251283 Zhu J.G. Huang X.P. Yang Y.P. Type IIFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus J. Immunol. 2007 178 3505 3510 17339445 Hartman Z.C. Kiang A. Everett R.S. Serra D. Yang X.Y. Clay T.M. Amalfitano A. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo J. Virol. 2007 81 1796 1812 10.1128/JVI.01936-06 17121790 Hartman Z.C. Black E.P. Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells Virology 2007 358 357 372 10.1016/j.virol.2006.08.041 17027060 Iacobelli-Martinez M. Nemerow G.R. Preferential activation of toll-like receptor nine by CD46-utilizing adenoviruses J. Virol. 2007 81 1305 1312 10.1128/JVI.01926-06 17108047 Basner-Tschakarjan E. Gaffal E. O'Keeffe M. Tormo D. Limmer A. Wagner H. Hochrein H. Tuting T. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production J. Gene Med. 2006 8 1300 1306 10.1002/jgm.964 Shayakhmetov D.M. Li Z.Y. Ternovoi V. Gaggar A. Gharwan H. Lieber A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses J. Virol. 2003 77 3712 3723 10.1128/JVI.77.6.3712-3723.2003 12610146 Cerullo V. Seiler M.P. Mane V. Brunetti-Pierri N. Clarke C. Bertin T.K. Rodgers J.R. Lee B. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors Mol. Ther. 2007 15 378 385 10.1038/sj.mt.6300031 17235317 Di Paolo N.C. Miao E.A. Iwakura Y. Murali-Krishna K. Aderem A. Flavell R.A. Papayannopoulou T. Shayakhmetov D.M. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo Immunity 2009 31 110 121 10.1016/j.immuni.2009.04.015 19576795 Wickham T.J. Mathias P. Cheresh D.A. Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment Cell 1993 73 309 319 10.1016/0092-8674(93)90231-E 8477447 Greber U.F. Willetts M. Webster P. Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells Cell 1993 75 477 486 10.1016/0092-8674(93)90382-Z 8221887 Chen C.J. Kono H. Golenbock D. Reed G. Akira S. Rock K.L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells Nat. Med. 2007 13 851 856 10.1038/nm1603 17572686 McCaffrey A.P. Fawcett P. Nakai H. McCaffrey R.L. Ehrhardt A. Pham T.T. Pandey K. Xu H. Feuss S. Storm T.A. Kay M.A. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver Mol. Ther. 2008 16 931 941 10.1038/mt.2008.37 18388926 Hasbrouck N.C. High K.A. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects Gene Ther. 2008 15 870 875 10.1038/gt.2008.71 18432276 Mingozzi F. High K.A. Immune responses to AAV in clinical trials Curr. Gene Ther. 2007 7 316 324 10.2174/156652307782151425 17979678 Zaiss A.K. Liu Q. Bowen G.P. Wong N.C. Bartlett J.S. Muruve D.A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors J. Virol. 2002 76 4580 4590 10.1128/JVI.76.9.4580-4590.2002 11932423 Zhu J. Huang X. Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice J. Clin. Invest. 2009 119 2388 2398 10.1172/JCI37607 19587448